Cargando…

CD74: a new prognostic factor for patients with malignant pleural mesothelioma

BACKGROUND: The pro-inflammatory cytokine migration inhibitory factor (MIF) and its receptor CD74 have been proposed as possible therapeutic targets in several cancers. We studied the expression of MIF and CD74 together with calretinin in specimens of malignant pleural mesothelioma (MPM), correlatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otterstrom, C, Soltermann, A, Opitz, I, Felley-Bosco, E, Weder, W, Stahel, R A, Triponez, F, Robert, J H, Serre-Beinier, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992494/ https://www.ncbi.nlm.nih.gov/pubmed/24594996 http://dx.doi.org/10.1038/bjc.2014.117

Ejemplares similares

Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis
por: Thies, Svenja, et al.
Publicado: (2015)

Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma
por: D'Amato-Brito, Cintia, et al.
Publicado: (2016)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

GAS5 long non-coding RNA in malignant pleural mesothelioma
por: Renganathan, Arun, et al.
Publicado: (2014)

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
por: Petrausch, Ulf, et al.
Publicado: (2012)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Experimental Model of Human Malignant Mesothelioma in Athymic Mice
por: Colin, Didier J., et al.
Publicado: (2018)

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
por: Oehl, Kathrin, et al.
Publicado: (2018)

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients
por: Jennings, C J, et al.
Publicado: (2015)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
por: Dalton, L E, et al.
Publicado: (2013)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring
por: Cerciello, Ferdinando, et al.
Publicado: (2013)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2019)

Defining and targeting tumor-associated macrophages in malignant mesothelioma
por: Wu, Licun, et al.
Publicado: (2023)

Evaluating the effect of immune cells on the outcome of patients with mesothelioma
por: Chee, Serena J, et al.
Publicado: (2017)

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models
por: Barbone, Dario, et al.
Publicado: (2015)

Markers for the non-invasive diagnosis of mesothelioma: a systematic review
por: van der Bij, S, et al.
Publicado: (2011)

Genomic landscape of pleural and peritoneal mesothelioma tumours
por: Hiltbrunner, Stefanie, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
por: Schröder, Christina, et al.
Publicado: (2019)

Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
por: Sun, Suna, et al.
Publicado: (2022)

Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2022)

SV40 associated miRNAs are not detectable in mesotheliomas
por: Gee, G V, et al.
Publicado: (2010)

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
por: Schuberth, Petra C, et al.
Publicado: (2013)

Calprotectin: a novel biomarker for the diagnosis of pleural effusion
por: Sánchez-Otero, N, et al.
Publicado: (2012)

Quality of Life Is Not Deteriorated After Extrapleural Pneumonectomy vs. (Extended) Pleurectomy/Decortication in Patients With Malignant Pleural Mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ea9dlnklqkn9f1i8aoj9atdj0r